Brian Feagan
Overview
Explore the profile of Brian Feagan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Danese S, Rothenberg M, Lim J, Ding H, McBride J, Chen Y, et al.
Clin Gastroenterol Hepatol
. 2024 Dec;
PMID: 39694207
Background & Aims: Efmarodocokin alfa is an interleukin (IL)-22 agonist, with favorable pharmacokinetic properties and an acceptable safety profile. This study further explored the therapeutic potential of efmarodocokin alfa compared...
2.
Atreya R, Ferrante M, Panaccione R, Feagan B, Shchukina O, Jairath V, et al.
J Crohns Colitis
. 2024 Nov;
PMID: 39485390
Background And Aims: Normalization of high-sensitivity C-reactive protein [hs-CRP] and fecal calprotectin [FCP] are suggested Crohn's disease [CD] intermediate treatment targets. This analysis evaluates achievement of biomarker normalization and the...
3.
Falloon K, Forney M, Husni M, Feagan B, Rieder F
Am J Gastroenterol
. 2024 Oct;
120(1):106-114.
PMID: 39360937
Inflammatory bowel disease (IBD)-associated spondyloarthritis (SpA) is common but remains poorly understood. In this review article, we aimed to provide guidance regarding the diagnosis and management of this condition. For...
4.
Feagan B
Gastroenterol Hepatol (N Y)
. 2024 Aug;
20(5):287-289.
PMID: 39193075
No abstract available.
5.
Silverman A, Bouchiba H, Aelvoet A, Macdonald J, Dekker E, Zayadi A, et al.
Endosc Int Open
. 2024 Jun;
12(6):E799-E809.
PMID: 38904059
There is limited consensus on the optimal method for measuring disease severity in familial adenomatous polyposis (FAP). We aimed to systematically review the operating properties of existing endoscopic severity indices...
6.
Bass N, Feagan B
Gastroenterol Hepatol (N Y)
. 2023 Nov;
5(8 Suppl 17):3-20.
PMID: 37967447
No abstract available.
7.
Ferrante M, Irving P, Abreu M, Axler J, Gao X, Cao Q, et al.
J Crohns Colitis
. 2023 Oct;
18(3):416-423.
PMID: 37797293
Background And Aims: Durable clinical remission, endoscopic healing, and biomarker normalization are key treatment goals for Crohn's disease. The selective anti-interleukin-23 p19 inhibitor risankizumab has demonstrated efficacy and safety in...
8.
Hudesman D, Long M, Wolf D, Hanauer S, Ghosh S, Petersen A, et al.
Am J Gastroenterol
. 2023 Jul;
116(Suppl 1):S9.
PMID: 37461954
Background: True North is a phase 3, randomized, double-blind, placebo-controlled trial conducted at 285 sites in 30 countries (NCT02435992). Treatment with once-daily ozanimod (an oral sphingosine 1-phosphate [S1P] receptor modulator...
9.
Raygoza Garay J, Turpin W, Lee S, Smith M, Goethel A, Griffiths A, et al.
Gastroenterology
. 2023 Jun;
165(3):670-681.
PMID: 37263307
Background & Aims: The cause of Crohn's disease (CD) is unknown, but the current hypothesis is that microbial or environmental factors induce gut inflammation in genetically susceptible individuals, leading to...
10.
Adedokun O, Xu Z, Gasink C, Kowalski K, Sandborn W, Feagan B
Clin Ther
. 2022 Sep;
44(10):1336-1355.
PMID: 36150926
Purpose: Ustekinumab, a fully human immunoglobulin G1κ monoclonal antibody that antagonizes human interleukin-12/23p40, is an effective therapy for several immune-mediated inflammatory diseases, including Crohn's disease (CD). This work characterizes the...